Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer

Abstract

Preferences were highly variable and influenced by women's unique circumstances and attitudes, but not by their anxiety or optimism scores.

When genomic and standard test results diverge: implications for breast cancer patients’ preference for chemotherapy

“…This suggests that one of the main promises of this test, allowing some women to safely forgo the substantial discomforts and potential risks associated with chemotherapy, may be harder to fulfill than previously hoped. Some women may view chemotherapy as a potential lifeline and be unwilling to sacrifice any means to increase the probability of cure, even when the incremental benefit is exceedingly small or non-existent [21].…”

Lung cancer clinicians’ preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?

“…Statistical methods were those used and validated in our previous preferences studies [5,7,[14][15][16][17]. Clinicians' preferences for adjuvant chemotherapy for NSCLC were described using the minimum extra survival benefit judged sufficient to make chemotherapy worthwhile in each of the 4 hypothetical scenarios.…”

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy

“…Many women with early-stage breast cancer are reluctant to decline chemotherapy due to concerns about the possibility of recurrence and a desire to do everything possible to fight their cancer [19–21]. These decisions can be driven by perceived risk of recurrence, distress related to the diagnosis, and the advantages and drawbacks women perceive regarding chemotherapy treatment (i.e., perceived pros and cons) [19, 22, 23]. We do not yet know whether receipt of their RS leads to a shift in these variables, or how these factors and the RS contribute to whether patients receive chemotherapy above and beyond the contribution of demographic and clinical variables.…”